MA56119A - Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques - Google Patents
Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiquesInfo
- Publication number
- MA56119A MA56119A MA056119A MA56119A MA56119A MA 56119 A MA56119 A MA 56119A MA 056119 A MA056119 A MA 056119A MA 56119 A MA56119 A MA 56119A MA 56119 A MA56119 A MA 56119A
- Authority
- MA
- Morocco
- Prior art keywords
- reagents
- reducing
- methods
- binding drug
- serological assays
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/34—Post-translational modifications [PTMs] in chemical analysis of biological material addition of amino acid(s), e.g. arginylation, (poly-)glutamylation, (poly-)glycylation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858871P | 2019-06-07 | 2019-06-07 | |
| US201962934395P | 2019-11-12 | 2019-11-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56119A true MA56119A (fr) | 2022-04-13 |
Family
ID=71899853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056119A MA56119A (fr) | 2019-06-07 | 2020-06-05 | Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200400662A1 (fr) |
| EP (1) | EP3980747A1 (fr) |
| JP (1) | JP7561775B2 (fr) |
| CN (1) | CN114206912B (fr) |
| MA (1) | MA56119A (fr) |
| WO (1) | WO2020247820A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016304794B2 (en) | 2015-08-07 | 2021-07-15 | ALX Oncology Inc. | Constructs having a SIRP-alpha domain or variant thereof |
| AU2017332960B2 (en) | 2016-10-20 | 2019-09-12 | I-Mab Biopharma Us Limited | Novel CD47 monoclonal antibodies and uses thereof |
| CN114126648A (zh) | 2019-05-31 | 2022-03-01 | Alx肿瘤生物技术公司 | 用SIRPα Fc融合体组合免疫检查点抑制剂治疗癌症的方法 |
| CN121243368A (zh) | 2019-11-27 | 2026-01-02 | Alx肿瘤生物技术公司 | 用于治疗癌症的组合疗法 |
| KR20230018475A (ko) | 2020-06-01 | 2023-02-07 | 알렉소 온콜로지 인크. | 암 치료용 저메틸화제를 포함하는 병용 요법 |
| TW202229861A (zh) * | 2020-10-14 | 2022-08-01 | 中國大陸商天境生物科技（上海）有限公司 | 藉由治療性抗cd47抗體於輸血前檢驗中減輕干擾之方法 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| EP4619435A1 (fr) | 2022-11-16 | 2025-09-24 | Boehringer Ingelheim International GmbH | Biomarqueurs d'efficacité prédictive pour anticorps anti-sirpa |
| CN116380580A (zh) * | 2023-03-15 | 2023-07-04 | 中国人民解放军空军军医大学 | 一种血浆检测前处理方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2111869A1 (fr) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions et procédés pour renforcer le système immunitaire |
| BR112012017164A2 (pt) | 2009-12-22 | 2019-09-24 | Novartis Ag | proteína de fusão de região constante de anticorpo-cd47 tetravalente |
| BR112013031762A2 (pt) | 2011-06-16 | 2016-09-13 | Novartis Ag | proteínas solúveis para utilização como terapêuticos |
| ES2816647T3 (es) | 2012-01-17 | 2021-04-05 | Univ Leland Stanford Junior | Reactivos SIRP-alfa de alta afinidad |
| KR102100388B1 (ko) | 2012-02-06 | 2020-04-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
| US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| DK3725807T3 (da) | 2012-12-03 | 2026-01-12 | Novimmune Sa | Anti-cd47 antistoffer og fremgangsmåder til anvendelse deraf |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| BR112015013431A2 (pt) | 2012-12-12 | 2017-11-14 | Vasculox Inc | anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos |
| PL3575326T3 (pl) | 2012-12-17 | 2022-07-11 | Pf Argentum Ip Holdings Llc | Leczenie komórek chorobowych cd47+ z użyciem fuzji sirp alfa-fc |
| NZ710695A (en) | 2013-02-06 | 2020-05-29 | Inhibrx Inc | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
| CN112245586A (zh) * | 2013-03-15 | 2021-01-22 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
| WO2016023040A1 (fr) | 2014-08-08 | 2016-02-11 | Alexo Therapeutics International | Constructions de variant sirp-alpha et leurs utilisations |
| EP3012271A1 (fr) | 2014-10-24 | 2016-04-27 | Effimune | Procédé et compositions pour induire la différenciation de cellule suppressives dérivées de myéloïde pour traiter le cancer et les maladies infectieuses |
| EP3221358B1 (fr) | 2014-11-18 | 2021-07-21 | Janssen Pharmaceutica, N.V. | Anticorps anti-cd47, procédés et utilisations |
| MX391051B (es) | 2014-12-30 | 2025-03-21 | Celgene Corp | Anticuerpos anti-cd47 y usos de los mismos. |
| PT3277821T (pt) | 2015-03-31 | 2019-10-31 | Novimmune Sa | Método para otimizar a montagem e produção de complexos proteicos hetero-multiméricos |
| CN106146670B (zh) | 2015-04-24 | 2019-01-15 | 宜明昂科生物医药技术（上海）有限公司 | 一种新的重组双功能融合蛋白及其制备和应用 |
| US10358472B2 (en) | 2015-05-06 | 2019-07-23 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity CD47 analogs |
| CN114425077A (zh) * | 2015-05-18 | 2022-05-03 | 起源生物医药公司 | Sirp多肽组合物和使用方法 |
| AU2016304794B2 (en) | 2015-08-07 | 2021-07-15 | ALX Oncology Inc. | Constructs having a SIRP-alpha domain or variant thereof |
| RU2748401C2 (ru) | 2015-09-18 | 2021-05-25 | Арч Онколоджи, Инк. | Терапевтические антитела к CD47 |
| WO2017053423A1 (fr) | 2015-09-21 | 2017-03-30 | Erasmus University Medical Center | Anticorps anti-cd47 et méthodes d'utilisation |
| WO2017068164A1 (fr) | 2015-10-21 | 2017-04-27 | Ose Immunotherapeutics | Procédés et compositions de modification de la polarisation des macrophages en cellules pro-inflammatoires pour traiter le cancer |
| PT3402820T (pt) | 2016-01-11 | 2020-08-20 | Forty Seven Inc | Anticorpos monoclonais anti-cd47 quiméricos, de ratinho ou humanizados |
| BR112018070823A2 (pt) | 2016-04-14 | 2019-02-05 | Ose Immunotherapeutics | anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno. |
| AU2017250029C1 (en) | 2016-04-15 | 2022-03-24 | Pfizer Inc. | Macrophage stimulation in CD47 blockade therapy |
| EP3454900A4 (fr) | 2016-05-09 | 2020-01-29 | Celgene Corporation | Anticorps cd47 et leurs méthodes d'utilisation |
| CN109689684B (zh) | 2016-07-06 | 2022-09-23 | 细胞基因公司 | 具有低免疫原性的抗体及其用途 |
| CN109862910A (zh) | 2016-08-03 | 2019-06-07 | 小利兰·斯坦福大学托管委员会 | 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效 |
| JOP20190009A1 (ar) * | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| AU2017332960B2 (en) | 2016-10-20 | 2019-09-12 | I-Mab Biopharma Us Limited | Novel CD47 monoclonal antibodies and uses thereof |
| EP3529276A4 (fr) | 2016-10-21 | 2020-06-17 | Arch Oncology, Inc. | Anticorps cd47 thérapeutiques |
| CA3042583A1 (fr) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Ameliorations de la therapie de blocage de cd47 par des inhibiteurs de hdac |
| CA3042581A1 (fr) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Amelioration de la therapie de blocage des cd47 par des inhibiteurs du proteasome |
| CN108779179B (zh) | 2016-11-28 | 2022-02-08 | 江苏恒瑞医药股份有限公司 | Cd47抗体、其抗原结合片段及其医药用途 |
| AU2017371070B2 (en) | 2016-12-09 | 2025-01-02 | Alector Llc | Anti-SIRP-alpha antibodies and methods of use thereof |
| JP7179743B2 (ja) | 2017-02-17 | 2022-11-29 | オーエスイー・イミュノセラピューティクス | 抗ＳＩＲＰｇ抗体の新規の使用 |
| JP7170331B2 (ja) | 2017-03-22 | 2022-11-14 | アーチ オンコロジー，インコーポレイテッド | 固形及び血液癌の治療のための併用療法 |
| WO2018183182A1 (fr) | 2017-03-27 | 2018-10-04 | Celgene Corporation | Procédés et compositions pour la réduction d'immunogénicité |
| CN110958888A (zh) | 2017-03-28 | 2020-04-03 | 延龄草治疗公司 | Cd47阻断疗法 |
| KR102702926B1 (ko) | 2017-04-13 | 2024-09-06 | 사이로파 비.브이. | 항-sirp 알파 항체 |
| CN118271443A (zh) | 2017-05-16 | 2024-07-02 | 拜奥迪斯私人有限公司 | 抗SIRPα抗体 |
| US20190062428A1 (en) | 2017-06-19 | 2019-02-28 | Surface Oncology, Inc. | Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof |
| WO2018237168A1 (fr) | 2017-06-21 | 2018-12-27 | The Board Of Trustees Of The Leland Stanford Junior University | Paramètres de dosage pour des thérapies ciblant cd47 à des malignités hématologiques |
| BR112020001653A2 (pt) | 2017-07-26 | 2020-07-21 | Forty Seven, Inc. | anticorpos anti-sirp-alfa e métodos relacionados |
| CN109422811A (zh) | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
-
2020
- 2020-06-05 US US16/894,468 patent/US20200400662A1/en not_active Abandoned
- 2020-06-05 JP JP2021572418A patent/JP7561775B2/ja active Active
- 2020-06-05 WO PCT/US2020/036425 patent/WO2020247820A1/fr not_active Ceased
- 2020-06-05 MA MA056119A patent/MA56119A/fr unknown
- 2020-06-05 EP EP20750429.1A patent/EP3980747A1/fr active Pending
- 2020-06-05 CN CN202080041810.5A patent/CN114206912B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020247820A1 (fr) | 2020-12-10 |
| JP7561775B2 (ja) | 2024-10-04 |
| CN114206912B (zh) | 2025-02-11 |
| JP2022535286A (ja) | 2022-08-05 |
| CN114206912A (zh) | 2022-03-18 |
| US20200400662A1 (en) | 2020-12-24 |
| EP3980747A1 (fr) | 2022-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56119A (fr) | Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques | |
| EP2438442A4 (fr) | Procédés et dosages pour mesurer p95 et/ou p95 dans un échantillon et anticorps spécifiques de p95 | |
| EP2254568A4 (fr) | Procédés et dosages pour détecter et traiter une hypoglycémie | |
| MA53338A (fr) | Dosages pour détecter la neurodégénérescence | |
| EP3504347A4 (fr) | Procédés de détection de changements de copie génomique dans des échantillons d'adn | |
| WO2008048300A3 (fr) | Biocapteur de détection pathogène | |
| EP2092355A4 (fr) | Ressources de partage dans un système pour éprouver des dispositifs semi-conducteurs | |
| MX2008014293A (es) | Metodos de ensayo sin separacion. | |
| EP3867397A4 (fr) | Procédés et réactifs pour le génotypage efficace de grands nombres d'échantillons par regroupement | |
| RU2020129667A (ru) | Способ детектирования молекулы-мишени и набор для использования в этом способе | |
| WO2015191546A3 (fr) | Réactifs de détection d'adp-ribose | |
| EP3464598A4 (fr) | Dosages d'analytes basés sur les aptamères | |
| EP2269065A4 (fr) | Procédés et réactifs pour augmenter la sensibilité d'une détection métallographique par enzyme | |
| ATE466108T1 (de) | Optoelektronisches detektionssystem | |
| EP3719499A4 (fr) | Procédé de dosage et kit de dosage pour l'antigène s du virus de l'hépatite b | |
| EP2232264A4 (fr) | Réactif d'extraction d'un immunosuppresseur pour dosages immunologiques | |
| EP3853612A4 (fr) | Méthodes et réactifs de dosages immunologiques du virus zika | |
| EP2344884A4 (fr) | Dosage semi-séquentiel pour la détection d'un analyte dans un échantillon | |
| EP3859338A4 (fr) | Réactif de dosage de l'hémoglobine, kit de dosage et procédé de dosage | |
| EP3387429A4 (fr) | Dispositif doté de procédés intégrés pour la réaction de polymérase en chaîne par transcription inverse (rt-pcr) et/ou d'analyses sur la base de matrice d'adn/protéines | |
| EP2367959A4 (fr) | Procédés et réactifs pour raccourcir les temps d'incubation dans des dosages par hybridation | |
| EP1891108A4 (fr) | Réactifs et dosages diagnostiques permettant de détecter la protéine psp94 | |
| EP2239575A4 (fr) | Réactif pour détecter un antigène de vih-1 et procédé de détection | |
| EP3433377A4 (fr) | Dosages et procédés pour détecter l'udp-glucose | |
| EP3857226A4 (fr) | Procédés et compositions pour éliminer l'interférence de la biotine dans des dosages à l'aide de pièges moléculaires conjugués |